IP Verse

Mylan Pharmaceuticals competitive analysis

Latest PTAB cases involving Mylan Pharmaceuticals

Discover the latest PTAB cases involving Mylan Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Last updated on: Feb 1, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Mylan Pharmaceuticals

IPR2023-00722Mar 16, 2023MYLAN PHARMACEUTICALSNOVO NORDISKInstitution Denied
IPR2023-00723Mar 16, 2023MYLAN PHARMACEUTICALSNOVO NORDISKInstitution Denied
IPR2023-00724Mar 16, 2023MYLAN PHARMACEUTICALSNOVO NORDISKTerminated-Settled
IPR2023-00099Oct 28, 2022MYLAN PHARMACEUTICALSREGENERON PHARMACEUTICALSInstitution Denied
IPR2022-01225Jul 1, 2022MYLAN PHARMACEUTICALSREGENERON PHARMACEUTICALSFinal Written Decision
IPR2022-01226Jul 1, 2022MYLAN PHARMACEUTICALSREGENERON PHARMACEUTICALSFinal Written Decision
IPR2022-01102Jun 10, 2022MYLAN PHARMACEUTICALSBAUSCH HEALTH IRELANDInstitution Denied
IPR2022-01103Jun 10, 2022MYLAN PHARMACEUTICALSBAUSCH HEALTH IRELANDInstitution Denied
IPR2022-01104Jun 10, 2022MYLAN PHARMACEUTICALSBAUSCH HEALTH IRELANDInstitution Denied
IPR2022-01105Jun 10, 2022MYLAN PHARMACEUTICALSBAUSCH HEALTH IRELANDInstitution Denied

Peer Comparison New

IP litigation analysis comparing Mylan Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jan 29, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MYLAN PHARMACEUTICALS - - 94 -
ALLERGAN11291333
ASTRAZENECA - 27 - 18
SANOFI AVENTIS DEUTSCHLAND1631 - 24